The Efficacy of Qianglidingxuan Tablets in the Treatment of Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

269 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-09

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research purpose: This study was a multicenter, randomized, double-blind, placebo-controlled, post-marketing clinical study in Chinese patients with essential hypertension to evaluate the efficacy and safety of Qianglidingxuan tablets(QLT) in the treatment of blood pressure in patients with mild to moderate essential hypertension.

1. Subject:

Patients diagnosed as essential hypertension with clinical grade 1-2.
2. Interventions:

①Basic treatment plan:Patients in both groups were required to have a low-salt, low-fat diet, quit smoking, limit alcohol, eat more vegetables, moderate exercise, control body weight, and amlodipine besylate tablets (5mg, QD).

②Treatment group: Based on the basic treatment, QLT was given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

③Control group: Based on basic treatment, QLT mimetic were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
3. Treatment and follow-up cycle:

Patients in both groups were treated for 12 weeks and followed up to the end of 48th week after treatment.
4. Provisions of concurrent treatment:

Any combined treatment used during the study should be recorded in the CRF, including drug name (generic name/trade name), starting time, administration dose, method of administration, termination time, indication, etc
5. Efficacy evaluation:

①Primary outcome measure: the change from baseline in office blood pressure after 12 weeks of treatment.

②Secondary efficacy indicators: 24-hour ambulatory blood pressure, heart rate, blood lipids, homocysteine, CRP, baPWV. TCM syndromes (including vertigo, headache, impatience and irritability, red face, red eyes, dry mouth, bitter mouth, tinnitus, insomnia, multiple dreams, constipation, urination, etc.)

③Safety indicators: adverse events, vital signs, physical examination, laboratory examination
6. Statistics:

SAS® 9.4 was used for all statistical analyses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Internet Medical Models for the Management of Patients With Hypertension in China

NCT03527563

Hypertension

UNKNOWN NA

The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble

NCT06116357

Primary Hypertension

NOT_YET_RECRUITING NA

Compare the Effects of Telemedicine Approach With Usual Care in Hypertension Management in China

NCT02919033

Hypertension

UNKNOWN NA

Blood Pressure Follow-up Study in Two Chinese Cohorts(C-BPCS)

NCT02734472

Hypertension

UNKNOWN

Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care

NCT02046993

Hypertension Blood Pressure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Medicine, Chinese Traditional

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Based on basic treatment, Qianglidingxuan mimetics were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Qianglidingxuan Tablets:

Specifications: 60 tablets per bottle; Storage: airtight, moisture-proof; Active ingredients:Gastrodia elata, Eucommia ulmoides, wild chrysanthemum, Eucommia ulmoides leaves, Chuanxiong; Manufacturer: Shaanxi Hanwang Pharmaceutical Co., LTD.

Group Type EXPERIMENTAL

Treatment group

Intervention Type DRUG

Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Control group

Based on basic treatment, Qianglidingxuan Tablets mimetics were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Qianglidingxuan Tablets mimetics:

Specifications: 60 tablets per bottle; Storage: airtight, moisture-proof; Active ingredients:NA; Manufacturer: Shaanxi Hanwang Pharmaceutical Co., LTD.

Group Type PLACEBO_COMPARATOR

Treatment group

Intervention Type DRUG

Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment group

Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women aged 18-75 years.
2. Patients diagnosed as essential hypertension with clinical grade 1-2.
3. Diagnosis of hyperactivity of liver Yang upper syndrome by TCM syndrome differentiation.
4. Patients signed the informed consent with good compliance and could cooperate with the follow-up and review.

Exclusion Criteria

1. Secondary hypertension: renal hypertension (renovascular hypertension, renal parenchymal hypertension), pheochromocytoma, primary aldosteronism, Cushing syndrome, abdominal aortic coarctation, etc.
2. Coronary atherosclerotic heart disease, acute attack of chronic heart failure, malignant arrhythmia, valvular heart disease, cardiomyopathy and other serious cardiovascular diseases.
3. Acute cerebrovascular diseases such as cerebral infarction and cerebral hemorrhage.
4. Severe psychological disorder, intellectual disability or language disorder, resulting in inability to fully cooperate with the study and inability to complete the study.
5. Any laboratory test index before screening met the following criteria: admission liver and kidney function indicated that ALT, AST \> 1.5 times the upper limit of normal value, Cr \> 1.2 times the upper limit of normal value (refer to the laboratory normal range of the research center); Other clinically significant laboratory abnormalities that were deemed unsuitable for enrollment by the investigator.
6. Allergic constitution or allergic to strong fixed glare tablets, excipients or similar ingredients of the trial drug.
7. Suspected or with a history of alcohol or drug abuse.
8. Pregnant, lactating women or those who plan to get pregnant recently or are unwilling to use contraceptive measures;.
9. Patients who had participated in other clinical trials within 3 months before enrollment.
10. Patients deemed by the investigator to be ineligible for enrollment in the trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No